aRCC: 1L Treatment Options and Patient Management

Avatar

How I Manage Immune Adverse Events in Solid Tumors

By Balazs Halmos 6 Videos
1,919 views
December 13, 2022
Comments 0
Login to view comments. Click here to Login
12:14

ASCO GU 2022 Update on CheckMate 214 With Extended 5-Year Follow-Up:…

ASCO Genitourinary Cancers Symposium

S. Tykodi

181 views
08:40

Overview of CheckMate 214: 5-Year Data on Nivo+Ipi in Patients With …

Thomas Hutson

98 views
16:00

ASCO GU 2022 Germline Mutations of Interests in Renal Cell Carcinoma

ASCO Genitourinary Cancers Symposium

M. Dean

190 views
09:23

ASCO GU 2022 on Molecular Alterations Across Sites of Metastasis in …

ASCO Genitourinary Cancers Symposium

R. McKay

77 views
16:34

ASCO GU 2022 Highlights on Adjuvant and Consolidative Therapy in Oli…

ASCO Genitourinary Cancers Symposium

N. Haas

144 views
06:04

ASCO 2022 on Safety & Clinical Activity of MEDI5752, a PD-1/CTLA-4 B…

ASCO 2022 Conference Coverage

L. Albiges

139 views
47:32

Mechanisms of Resistance and Toxicity to Immune Checkpoint Therapy i…

Moffitt Cancer Center

J. Gao

248 views
13:28

2022 ASCO Renal Cell Carcinoma Updates

Total Health

M. Bupathi

198 views
12:53

Dual Immunotherapy in RCC

O'Neal Comprehensive Cancer Center at UAB

A. Basu

548 views
20:47

ESMO 2022 on the Latest in mRCC

ecancer

J. Puente, B. Escudier, V. Grünwald, S. Oudard

195 views
21:09

Evolving Landscape of 1L Systemic Treatment in Metastatic Renal Cell…

Mário Fontes-Sousa

228 views
20:23

Choosing Wisely: 1L Combination Treatment for Advanced RCC

Aly-Khan A. Lalani

749 views
06:50

ESMO 2022 Updates in Renal Cancer

ecancer

T. Choueiri

292 views
10:55

Systemic Therapies for Clear Cell RCC: Where Are We Now?

Yale Cancer Center

D. Braun

468 views
14:14

GU Tumor Board: 61 y/o Male With mRCC With Disease Progression After…

PrecisCa

M. Rettig, S. Slovin, T. Fraum, J. Abel, P. Patel

204 views